Korro Bio, Inc.
NASDAQ:KRROBiotechnology
Healthcare
$12.32 +15.88%
+$1.76 today
- Market cap
- $169.10M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
52W Low $5.20High $55.89
Volume 0.16M
Average 0.15M
Income Statement
Follow revenue through to earnings.
Revenue
$6.39M
FY 2025 · Annual
+181.5% YoYOperating Income
-$87.34M
FY 2025 · Annual
Net Income
-$117.26M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| 4.45M | 255K | 1.53M | 8.92M | 9.4M | |
| 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
KRRO Earnings Waterfall · TTM
NASDAQ:KRRO · Revenue to Net Income
Key Ratios
EPS$-11.68
Gross Margin62.4%
Net Margin-1823.8%
P/E Ratio-2.4
P/S Ratio137.8
Analysis
$3.8M of revenue converted into -$113.5M of net income for the selected period. Gross margin is 62.4% and net margin is -1823.8%, showing how much revenue survives after costs and taxes. EPS is $-11.68, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 |
How much revenue does KRRO generate?
Korro Bio, Inc. (KRRO) reported $6.39M of revenue in fiscal 2025.
Is KRRO profitable?
Korro Bio, Inc. (KRRO) reported -$117.26M of net income, with a net margin of -1834.5%.
Continue the stock analysis
Jump to another research area for this company.